In type 2 diabetes, increased serum galectin-9 correlates with declining GFR (67), while recombinant galectin-9 therapy in mouse models mitigates glomerular hypertrophy, albumin excretion, and TGF-β expression (68). Here, ALB is linked to type 2 diabetes mellitus.